DIANTHUS THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.01 USD | +7.08% |
|
+8.74% | +150.10% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 154.1 | 763.4 | - | - |
| Enterprise Value (EV) 1 | 154.1 | 449.9 | 244.9 | 763.4 |
| P/E ratio | -1.23 x | -11.4 x | -10.1 x | -8.36 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 54.5 x | 379 x | 331 x | 235 x |
| EV / Revenue | 54.5 x | 223 x | 106 x | 235 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -5.77 x | -2.86 x | -7.77 x |
| FCF Yield | - | -17.3% | -35% | -12.9% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 14,818 | 29,349 | - | - |
| Reference price 2 | 10.40 | 26.01 | 26.01 | 26.01 |
| Announcement Date | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 2.826 | 2.014 | 2.307 | 3.249 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -48.17 | -78.16 | -98.55 | -132.9 |
| Operating Margin | - | -1,704.67% | -3,881.56% | -4,271.68% | -4,089.98% |
| Earnings before Tax (EBT) 1 | - | -43.56 | -66.68 | -89.61 | -122.9 |
| Net income 1 | -28.48 | -43.56 | -66.68 | -89.61 | -122.9 |
| Net margin | - | -1,541.22% | -3,311.71% | -3,884.11% | -3,782.46% |
| EPS 2 | -7.100 | -8.450 | -2.283 | -2.570 | -3.110 |
| Free Cash Flow 1 | - | - | -78 | -85.74 | -98.21 |
| FCF margin | - | - | -3,873.66% | -3,716.3% | -3,023.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/1/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.924 | 0.457 | 0.874 | 0.3764 | 0.3764 | 0.3764 | 0.4785 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -15.76 | -12.96 | -17.84 | -18.78 | -20.09 | -21.46 | -18.91 |
| Operating Margin | -1,705.52% | -2,835.01% | -2,041.65% | -4,989.69% | -5,338.47% | -5,700.69% | -3,951.62% |
| Earnings before Tax (EBT) 1 | -14.76 | -10.56 | -13.75 | -16.28 | -17.64 | -19.04 | -15.63 |
| Net income 1 | -14.76 | -10.56 | -13.75 | -16.28 | -17.64 | -19.04 | -15.63 |
| Net margin | -1,597.73% | -2,311.38% | -1,573% | -4,324.34% | -4,686.13% | -5,058.55% | -3,265.62% |
| EPS 2 | -3.780 | - | -0.5400 | -0.5820 | -0.6260 | -0.6440 | -0.5000 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/9/23 | 3/21/24 | 5/9/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 314 | 519 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -78 | -85.7 | -98.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.13 | 0.18 | 0.21 |
| Capex / Sales | - | - | 6.36% | 7.98% | 6.42% |
| Announcement Date | 8/1/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
26.01
USD
Average target price
50.83
USD
Spread / Average Target
+95.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +150.10% | 713M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- DNTH Stock
- Financials Dianthus Therapeutics, Inc.
